Keyphrases
Phase II Study
100%
Fallopian Tube
100%
Bevacizumab
100%
Primary Peritoneal Cancer
100%
Pemetrexed
100%
Progression-free Survival
60%
Epithelial Ovarian Cancer
60%
Platinum Sensitivity
40%
Response Rate
20%
Hematological Malignancies
20%
Anemia
20%
Neutropenia
20%
Overall Survival
20%
Median Overall Survival
20%
Median Progression-free Survival
20%
Nonhematologic
20%
Complete Response
20%
Partial Response
20%
Hematotoxicity
20%
Thrombocytopenia
20%
Gastrointestinal
20%
Prior Chemotherapy
20%
Taxanes
20%
Stable Disease
20%
Progressive Disease
20%
Metabolic
20%
Chemotherapy Regimen
20%
Leukopenia
20%
Following Response
20%
Treatment Cycle
20%
0-complete
20%
Platinum-free Interval
20%
Medicine and Dentistry
Bevacizumab
100%
Primary Peritoneal Cancer
100%
Pemetrexed
100%
Fallopian Tube
100%
Progression Free Survival
80%
Krukenberg Tumor
60%
Overall Survival
40%
Health Care Cost
20%
Neutropenia
20%
Anemia
20%
Hematologic Malignancy
20%
Patient History of Chemotherapy
20%
Progressive Disease
20%
Thrombocytopenia
20%
Leukopenia
20%
Chemotherapy
20%
Diseases
20%
Pharmacology, Toxicology and Pharmaceutical Science
Bevacizumab
100%
Pemetrexed
100%
Peritoneum Cancer
100%
Progression Free Survival
80%
Ovary Carcinoma
60%
Overall Survival
40%
Diseases
40%
Hematologic Malignancy
20%
Anemia
20%
Neutropenia
20%
Chemotherapy
20%
Thrombocytopenia
20%
Patient History of Chemotherapy
20%
Leukopenia
20%
Taxane
20%